Tech Company Financing Transactions
Prellis Biologics Funding Round
Prellis Biologics secured a $14.5 million Series B funding round on 12/17/2021. Backers included Celesta Capital, Khosla Ventures and IndieBio.
Transaction Overview
Company Name
Announced On
12/17/2021
Transaction Type
Venture Equity
Amount
$14,500,000
Round
Series B
Investors
Proceeds Purpose
The company plans to use this round to move from an R&D driven company to a product focused one -- which means developing more drug partnerships, and demonstrating the platform's capability.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
900 Indiana St.
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Prellis Biologics, we are driven by our vision of a world where functional human tissues can be created on demand in a laboratory setting.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Melanie Matheu
Controller
Matthew Niemiec
VP - Bus. Development
Diana Bogorodskaya
VP - Engineering
Erik Busby
Browse more venture capital transactions:
Prev: 12/17/2021: AvantStay venture capital transaction
Next: 12/17/2021: Innovaccer venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs